Asia-Pacific Gene Therapy Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2026 - 2032)

Asia-Pacific Gene Therapy Market Trends and Drivers

Vector Diversification Is Key Trend Reshaping Therapeutic Development Strategies

Therapeutic developers across Asia-Pacific are increasingly exploring delivery platforms beyond conventional viral vectors as researchers seek to address limitations related to immunogenicity, payload capacity, manufacturing complexity, and repeat dosing. A 2024 review of global gene therapy clinical development identified approximately 3,900 gene therapy clinical trials completed, ongoing, or approved worldwide through 2023, with viral vectors continuing to account for a substantial proportion of clinical development. AAV remains a leading platform for in vivo gene delivery, while lentiviral, adenoviral, and other viral vectors continue to support specific therapeutic applications.

At the same time, non-viral delivery systems, including lipid nanoparticles (LNPs) and GalNAc-based platforms, are gaining clinical attention, supported by their potential to address some limitations associated with viral vectors. This diversification is encouraging developers and manufacturers to evaluate multiple delivery technologies, broadening the range of vector platforms available for gene therapy development across the region.

Rising Rare Disease Burden Is Biggest Driver

Asia-Pacific's large and diverse population, combined with the substantial burden of rare and genetic disorders, is expanding the potential patient pool for advanced therapies. According to IQVIA, an estimated 258 million people in the Asia-Pacific region are affected by rare diseases, highlighting the substantial unmet medical need and potential addressable patient population for innovative treatments. The large patient base provides developers with opportunities to conduct clinical research across diverse populations and supports demand for therapies targeting rare and inherited disorders with limited treatment options.

The increasing identification and diagnosis of rare genetic diseases are improving patient visibility and supporting clinical-trial recruitment, while expanding regulatory frameworks and specialized treatment infrastructure across major APAC markets are facilitating the development of advanced therapies. Rising diagnosis and identification of rare genetic disorders are increasing the visibility of eligible patient populations, supporting clinical-trial recruitment and encouraging pharmaceutical and biotechnology companies to expand development programs for therapies targeting previously underserved conditions.

Reimbursement Fragmentation Is Key Restraint

Despite regulatory progress, fragmented reimbursement frameworks remain a significant restraint on the adoption of gene therapies across Asia-Pacific. Gene therapies often involve high upfront treatment costs, making reimbursement coverage critical for patient access. A peer-reviewed analysis published in Cytotherapy indicates that Japan and South Korea have established reimbursement mechanisms for selected cell and gene therapies following health technology assessment, while reimbursement availability remains more limited across several other APAC markets. Differences in insurance coverage, health technology assessment procedures, and government funding mechanisms therefore create uneven access to these treatments across the region.

Limited reimbursement can shift a substantial portion of treatment costs to patients, particularly in markets where public or private insurance coverage for advanced therapies remains underdeveloped. This can restrict the number of eligible patients who can afford treatment, delay adoption of newly approved therapies, and reduce commercial uptake even after regulatory approval. Differences in reimbursement policies and healthcare financing capacity across APAC can create a gap between regulatory approval and actual patient access, limiting the conversion of clinical and regulatory advances into broader treatment adoption.

Government-Backed Biomanufacturing Investment Is Biggest Opportunity

Government-backed investment in biotechnology, regenerative medicine, and advanced-therapy infrastructure is creating opportunities for gene therapy developers and manufacturers to establish and scale regional capabilities across Asia-Pacific. Japan's AMED funding programs have allocated approximately JPY 350 billion to support the pharmaceutical startup and drug-discovery venture ecosystem, providing early-stage companies with access to public financing and reducing dependence on private capital. In India, the Department of Biotechnology and BIRAC launched a 2025 joint funding program specifically targeting cell and gene therapy and high-performance biomanufacturing under the BioE3 Policy, including projects focused on gene therapies for inherited hematological diseases, CAR-T therapies, and viral and non-viral gene-delivery technologies.

The expansion of such targeted public funding programs creates an opportunity for gene therapy developers, CDMOs, vector manufacturers, and research institutions to establish development and manufacturing capabilities in APAC markets. India's program, in particular, supports both early-stage research and scale-up activities, creating opportunities to bridge the gap between laboratory development and commercial manufacturing.

Asia-Pacific Gene Therapy Market Segmentation Analysis

Type Analysis

The in-vivo category holds the larger market share, of 75%, in 2025, supported by the growing clinical and commercial use of direct gene delivery, particularly through viral-vector platforms such as adeno-associated virus (AAV). AAV-based approaches remain prominent in the development of in-vivo gene therapies, supported by continued clinical advancement and regulatory activity for AAV-based treatments in major Asia-Pacific markets. This established development base and expanding application across inherited and other genetic disorders support the segment's leading position.

The ex-vivo category will have the higher CAGR, of approximately 33.0%, supported by increasing development of genetically modified cell therapies, particularly CAR-T, alongside expanding cell-processing and manufacturing capabilities in China, Japan, and India. The approval and commercialization of domestically developed CAR-T therapies, including China's FKC876 and India's NexCAR19, demonstrate the region's growing capacity to develop and manufacture genetically modified cell therapies. Increasing clinical adoption in hematological malignancies and improvements in cell-engineering and manufacturing processes are further strengthening the development pipeline for ex-vivo approaches.

The types analyzed in this report are:

• In Vivo (Larger Category)
• Ex Vivo (Faster-Growing Category)

Vector Type Analysis

The adenovirus category holds the largest market share, of 60%, in 2025, supported by its established clinical experience, manufacturing infrastructure, and continued use in selected gene therapy applications. Its established production processes and accumulated clinical expertise provide developers with a relatively mature platform for vector development and manufacturing.

The non-viral category will have the highest CAGR, of approximately 33.2%, supported by increasing development of lipid nanoparticle (LNP), plasmid DNA, and other non-viral delivery technologies, which provide alternatives to viral vectors for selected gene-delivery applications. Increasing research into gene editing and nucleic-acid-based therapies is broadening the potential applications of non-viral delivery systems, while their potential for repeat administration and flexible payload delivery is encouraging further development.

The vector types analyzed in this report are:

• Adenovirus (Largest Category)
• Non-Viral (Fastest-Growing Category)
• Herpes Simplex Virus (HSV)

Application Analysis

The carcinoma category holds the largest market share, of 40%, in 2025, supported by the region's substantial cancer burden, extensive oncology clinical-development activity, and growing use of gene-modified and viral-vector therapies across cancer indications. The expansion of CAR-T therapies for hematological malignancies and increasing development of gene-based approaches for solid tumors are broadening the application of gene therapy in oncology, while the large regional patient population provides a substantial pool for clinical development and treatment adoption.

The acute lymphoblastic leukemia category will have the highest CAGR, driven by the increasing adoption of CAR-T cell therapies, growing clinical validation of genetically modified cell therapies in relapsed or refractory B-cell ALL, and expanding cell-therapy development and manufacturing capabilities across Asia-Pacific. The U.S. FDA approved obecabtagene autoleucel in November 2024 for adults with relapsed or refractory B-cell precursor ALL, adding another CD19-directed CAR-T therapy to the treatment landscape. This regulatory progress reflects continued development of genetically modified cell therapies for ALL and strengthens the clinical evidence base supporting expansion of this application.

The applications analyzed in this report are:

• Carcinoma (Largest Category)
• Nasopharyngeal Cancer
• Acute Lymphoblastic Leukemia (ALL) (Fastest-Growing Category)
• Critical Limb Ischemia
• Melanoma

End User Analysis

The pharmaceutical and biotechnology companies category holds the larger market share, of 80%, in 2025, supported by the substantial capital and technical requirements associated with gene therapy development, clinical trials, viral-vector manufacturing, regulatory compliance, and commercialization. Pharmaceutical and biotechnology companies possess greater financial resources and specialized infrastructure to advance therapies from discovery through clinical development and commercial production, giving them a larger role in gene therapy activities than academic institutions and research centers.

The academic institutes and research centers category will have the higher CAGR, supported by increasing government funding, academic-industry collaborations, and the expansion of translational research programs focused on gene and cell therapies. For example, India's Department of Biotechnology and BIRAC have supported indigenous cell and gene therapy development through programs targeting advanced-therapy research and biomanufacturing, strengthening the role of academic institutions in early-stage discovery and translational development. Increasing collaboration between academic researchers, biotechnology companies, and government agencies is enabling more gene therapy candidates to progress from laboratory research toward clinical development.

The end users analyzed in this report are:

• Pharmaceutical and Biotechnology Companies (Larger Category)
• Academic Institutes and Research Centers (Faster-Growing Category)

Asia-Pacific Gene Therapy Market Regional Analysis

China Gene Therapy Market Size

China holds the largest market share, of 40%, in 2025, supported by an expanding biomanufacturing base, a growing pipeline of domestically developed viral-vector therapies, and evolving regulatory pathways under the National Medical Products Administration (NMPA). According to China's Center for Drug Evaluation (CDE), 115 cell and gene therapy clinical trials were registered in 2024, representing a 42% increase from 2023, highlighting the country's rapidly expanding clinical development activity in advanced therapies. In April 2025, the NMPA approved BBM-H901 (dalnacogene ponparvovec) for the treatment of adults with moderate-to-severe hemophilia B, making it China's first approved gene therapy for hemophilia B. Developed and manufactured by Shanghai-based Belief BioMed, the therapy uses a recombinant adeno-associated virus (rAAV) vector and represents a significant milestone for China's domestic gene therapy industry.

India Gene Therapy Market Size

India will have the highest CAGR, of approximately 33.7%, supported by government-backed indigenous cell and gene therapy development, expanding academic-industry translational partnerships, and growing domestic manufacturing capabilities. India's Department of Biotechnology and Biotechnology Industry Research Assistance Council (BIRAC) supported the development of NexCAR19, India's first indigenous CAR-T cell therapy, highlighting the country's growing capabilities in advanced therapies. Indian Institute of Technology Bombay confirms that NexCAR19 received marketing authorization from India's Central Drugs Standard Control Organization (CDSCO) for the treatment of relapsed/refractory B-cell lymphomas and leukemia. The development and regulatory approval of indigenous CAR-T therapies demonstrate India's expanding capacity to translate advanced-therapy research into commercially available treatments, supporting the country's gene therapy market growth during the forecast period. Expanding public research funding, a large and genetically diverse patient population, and increasing domestic manufacturing capabilities are further expected to support the development and adoption of advanced therapies in India.

The countries of the market are as follows:

• China (Largest Country)
• India (Fastest-Growing Country)
• Japan
• South Korea
• Australia
• Rest of World

Asia-Pacific Gene Therapy Market Competitive Landscape

The market is fragmented, with competition distributed among multinational pharmaceutical companies, specialized biotechnology firms, regional manufacturers, and emerging domestic developers. High technology and capital requirements for vector development, manufacturing, clinical trials, and regulatory compliance create entry barriers, while the presence of multiple therapeutic platforms and disease-specific approaches allows numerous specialized players to operate simultaneously. China, Japan, India, and South Korea have also fostered domestic developers through government funding, research partnerships, and localized manufacturing initiatives. Companies such as Novartis, F. Hoffmann-La Roche, and Sibiono GeneTech, contribute to this fragmented structure through different approaches, including global commercialization, regional partnerships, domestic product development, and localized manufacturing. The absence of a single dominant player, combined with increasing participation from regional biotechnology companies and contract manufacturers, continues to shape the competitive landscape.

Asia-Pacific Gene Therapy Market Developments

• In August 2025, AnGes Inc. entered into an agreement with Boehringer Ingelheim BioXcellence for the manufacture and supply of the drug substance for its HGF gene therapy (Collategene) for peripheral arterial disease, supporting further development of the Japan-developed therapy.
• In January 2025, REGENXBIO Inc. entered into a strategic partnership with Nippon Shinyaku to develop and commercialize RGX-121 for MPS II in the U.S. and Asia, including Japan.